April 23, 2026 - To maintain scientific integrity and reduce the risk of costly settlements related to image fraud, we recommend institutions subscribe to image forensics tools, establish dedicated image forensics teams, and encourage researchers to screen their manuscripts before publication.
February 16, 2026 - In December 2025 and January 2026, our server encountered malicious cyberattacks that led to disruptions of online publications and website access.
January 1, 2026 - As we enter 2026, the scientific and publishing communities are facing a lot of challenges. In this environment, our journal aims to provide a platform for the open exchange of scientific ideas, including those that address important and, at times, controversial topics. We welcome diverse opinions and encourage authors to express and share their views —agree or disagree, your views are welcome. Authors of accepted papers will benefit from active post-publication promotion and opportunities to participate in round-table discussions and video interviews about their research.
June 4, 2025 – Impact Journals (Oncotarget's publisher) will sponsor
Team Open Access in the
Ride for Roswell annual cycling event to end cancer on Saturday, June 28, 2025. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, NY.
May 29, 2025 - At the Society for Scholarly Publishing (SSP) 47th Annual Meeting, Impact Journals (Oncotarget's publisher), received a "Certificate of Gratitude" for contributing to
SSP's Generations Fund.
October 22, 2024 - It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
Tribute to Dr. Blagosklonny.
On July 22, 2024,
Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. In celebration of the new additions, we are excited to offer a special discount of 50% on all publication fees until the end of the year.
Read the press release for further details.
On June 11, 2024, Impact Journals (Oncotarget's publisher) will sponsor
Team Open Access in the
Ride for Roswell annual cycling event to end cancer on Saturday, June 22, 2024. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, NY.
Learn More.
May 30, 2024 - At the Society for Scholarly Publishing (SSP) 46th Annual Meeting, Impact Journals (
Oncotarget’s publisher), received a
"Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion.
February 22, 2024 -
Oncotarget is a contributing sponsor at the International Centre for Genetic Engineering and Biotechnology (ICGEB)
19th International p53 Workshop from May 13–16, 2024, in Trieste, Italy.
Learn More.
On June 1, 2023, at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, Impact Journals (Oncotarget's publisher), received a
"Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.
Learn More.
On May 17, 2023, Impact Journals (Oncotarget's publisher) will sponsor
Team Open Access in the
Ride for Roswell annual cycling event to end cancer on Saturday, June 24, 2023. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, NY.
Learn More.
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Learn more.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.
Learn more.
On June 25, 2022 – Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York.
Learn more.
On June 2, 2022, at the Society for Scholarly Publishing (SSP) 44th Annual Meeting, Impact Journals, Oncotarget's publisher, received a "Certificate of Gratitude" for contributing to the SSP's Generations Fund. The Generations Fund provides long-term resources to the SSP's programs on leadership-workforce development and diversity, equity and inclusion.
Learn more.
June 1–3, 2022 – Impact Journals (Oncotarget's publisher) is a supporter and exhibitor at the
Society for Scholarly Publishing (SSP) 44th Annual Meeting. We will be presenting our full
scientific integrity process at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Learn more.
On March 28, 2022 – Impact Journals publishes scholarly journals in biomedical sciences with a focus on all areas of cancer and aging research. Impact Journals is participating as an
exhibitor at the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, the AACR conference is entitled, “Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.”
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
On September 23, 2021, Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) launched a new web page showcasing the full Oncotarget Scientific Integrity Process.
Read about it in greater detail on Oncotarget’s new Scientific Integrity web page.
The new page also showcasts a visual representation of the number of post-publication corrections and retractions by Oncotarget compared to the industry average between 2010 and 2021. As of September 23, 2021, Oncotarget’s rate of corrections/retractions is 2.87%. The industry average correction/retraction rate is 3.80%.
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
